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ABSTRACT 
Objectives: A systematic review of studies was undertaken to evaluate the potential 
effect of tocotrienols intake or its circulating levels on parameters associated with 
successful ageing (i.e., cognitive function, osteoporosis and DNA damage). Methods: 
Following PRISMA guidelines a systematic review of epidemiological observational 
studies and clinical trials was undertaken. Inclusion criteria included all English 
language publications in the databases PubMed and Scopus, until end of July 2016. 
Results: Evidence from prospective and case-control studies suggested that increased 
blood tocotrienols levels were associated with favorable cognitive function outcomes. 
Clinical trial with tocotrienols supplementation for 6 months suggested a beneficial 
role of tocotrienols intake on DNA damage rate, but only in elderly. Regarding 
osteoporosis, only in vitro studies with human bone cells cultures were identified, 
demonstrating significant inhibition of osteoclasts and promotion of osteoblasts 
activity. Conclusions: Research in middle-aged and elderly humans suggests potential 
beneficial anti-ageing action with respect to cognitive impairment and DNA damage, 
with other data limited to laboratory studies. Therefore, clinical trials are required to 
further elucidate the potential beneficial effects of tocotrienols on aspects associated 
with healthy ageing. 
Key words: tocotrienols; ageing; osteoporosis; cognitive function; systematic review. 
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1. INTRODUCTION 
The technical and biological definition of ageing initially was set as a time-
dependent functional decline that affects almost all living organisms and gradually 
leads to death. However, the ageing phenomenon and phenotype in humans has been 
proved to be far more complex (1). Therefore, despite the fact that specific biological 
processes have been recognized to promote ageing, there is still a lack of widely 
accepted ageing factors and markers (2). Academic interest in ageing has grown as a 
necessary response to the doubling in the global population of the elderly over the 
past 50 years. Public health frameworks have also identified well-being, active and 
healthy ageing  as their primary goals, aiming to reduce the burden of age-related 
morbidity, including osteoporosis, Alzheimer’s Disease (AD) and dementia (3). 
Relatively recent scientific advances in biomedical field have allowed for a range of 
biomarkers to be proposed to assess biological age including DNA damage 
(methylation), renal function, growth hormones and inflammatory markers (4).  
It has been proposed that a number of nutrients that can interact in a potentially 
synergistic manner to improve biomarkers associated with ageing, and as such these 
nutrients have been suggested as potential ageing inhibitors (5). Among several of 
these, vitamin E was considered one of the potent antioxidants especially in lipid 
systems, and as such via this mechanism had the potential to delay the ageing process 
(6). Apart from tocopherols (a vitamin E subtype), tocotrienols also have evoked 
research interest linked to the potential with respect to cellular protection (7, 8), 
neuroprotective actions (9, 10), anti-inflammatory effects (11) and also as 
antiosteoporotic agents per se (12, 13) or combined with statins (14). Unfortunately, 
the majority of the studies to date, have been limited to animal models and cell 
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cultures (15, 16), impeding the validity of applying any recommendations with 
respect to tocotrienols for humans with respect to healthy ageing.  
The aim of this systematic review was to provide an analysis of the published data 
to assess the effect of tocotrienols on age-related conditions including cognitive 
function impairment, osteoporosis and DNA damage rates in middle-aged men and 
women.    
 
2. METHODS 
The literature search, data extraction and systematic review were undertaken 
following the principles of the PRISMA 2009 guidelines (17).  
2.1 Eligibility Criteria 
Studies with samples consisting of men and/or women aged over 50 years that 
had either received tocotrienols’ supplementation or the intake of tocotrienols had 
been measured either as blood circulating levels or as dietary intake of tocotrienols.  
2.2 Information sources and search strategies 
 Original research studies published in English until July 31, 2016 were 
selected following a computer-assisted literature search of two online databases 
(PubMed, Scopus). Computer searches used combinations key words relating to the 
aim of the paper, i.e. “tocotrienol”, “ageing”, “aging” and “human”. In addition, the 
reference list of the retrieved articles was used to find relevant to the present articles 
that were not allocated through the searching procedure. The initial search resulted in 
67 unique entries across both databases. The relevance of studies was assessed by 
using a hierarchical approach based on: title, abstract, and the full manuscript. 
2.3 Study selection 
Commented [s1]: Panagiotakos uses only these two so we have 
to keep it this way. 
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Predefined research methodology was used by two authors (ENG and NN) 
who screened all the abstracts that were identified following the application the  
search criteria described before.  The full-texts of the articles that matched the 
eligibility criteria presented above, were read in order to reach the final number of the 
study that met the inclusion criteria. 
2.4 Study quality 
Exclusion criteria for the clinical trials included lack of randomization, lack of 
control group and non-human studies. Observational studies and clinical trials not 
published in English and studies that performed a post-hoc analysis of previous 
published studies, already selected for this review, were also excluded.  
2.5 Data items 
 The recorded aspects included the study design, the number of the 
participants, the exposure and the outcome for prospective studies, the duration of 
follow-up, the intervention and the placebo for clinical trials and the measuring way 
of tocotrienols intake.  
2.6 Data collection process 
As presented in Figure 1, of the initial 67 studies that were extracted from the 
electronic databases, only 7 studies (3 observational studies, 1 clinical trial and 3 in 
vitro studies with human bone cells) were included on the basis of the title or abstract 
(i.e., relevant research hypothesis studied).  
[Figure 1] 
3. RESULTS 
Cognitive function 
Case-control studies 
Commented [Uo2]: Did we include any bias scoring eg. 
Newcastle-Ottawa or similar? 
Commented [s3R2]: No because we had in vitro as well. So 
quality is approached by exclusion/inclusion criteria. Are you OK 
with that? 
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A cross-sectional study, that derived a sub-group consisting of 168 patients 
with AD, 166 with Mild Cognitive Impairment and 187 controls from a multicenter 
European study, assessed the cognitive function among elderly using the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV) and other validated tools and 
revealed that the plasma tocotrienols levels are inversely linked with cognitive 
function. More specifically, serum total tocotrienols were significantly higher in 
controls as compared to AD patients (118 vs. 91 nM/mmol cholesterol, p<0.05). 
When this data was further analyzed using a multivariable analysis adjusted for age, 
gender, educational status, APOE genetic profile, residential location and disease 
duration, being in the highest tertile of tocotrienols levels was associated with almost 
95% lower odds of having AD as compared with lowest tocotrienols tertiles (Odds 
Ratio (OR)=0.06, 95% Confidence Intervals (CI): 0.02-0.21). The authors suggested 
that α-tocotrienol prevents regulates cell death and prevents neurodegeneration. 
Strengths of this study were the assessment of several types of vitamin E, which 
provides safe findings results for the effect of tocotrienols, but its cross-sectional 
design cannot provide causal associations (18).  
Prospective studies 
The first prospective study which evaluated the impact of circulating 
tocotrienols' levels in a Swedish cohort at risk of developing AD risk was reported in 
2010. The study sample consisted of 232 AD-free older adults (aged >80 years of age) 
who were part of the Kungsholmen Project. At baseline examination, all the 
circulating vitamin-E subtypes were measured, including tocotrienols. During the 6-
year follow-up period the individuals who were in the highest tertile of circulating 
total tocotrienols had reduced risk of developing AD as compared to those in the 
lowest tertile (Hazard Ratio (HR)=0.46, 95% CI: 0.23-0.92), even after adjusting for 
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potential confounders.  However, when the different vitamin E subtypes were 
separately evaluated, no significant association was detected between different 
tocotrienol types and 6-year AD risk (HR for α-tocotrienol=0.70, 95% CI: 0.44-1.11, 
HR for beta-tocotrienol=0.69, 95% CI: 0.45-1.06).  The authors suggested that it is 
the total amount and combination of tocotrienol types that affect the cell metabolism, 
which is linked to cognitive function, not the specific type of tocotrienols. The latter 
raised important questions concerning the translation of those findings in dietetic 
advice and supplementation guidance, which still remain unknown. Unfortunately, no 
information regarding vitamin E dietary intake was obtained, thus, there is no 
information regarding the link between serum tocotrienol levels, dietary intake and 
AD risk (19).  
The second prospective study in this area, conducted by the same research 
group in 140 Finnish older adults, over an 8-year follow-up period and assessed the 
role of several vitamin E types on the development of cognitive impairment in AD-
free participants.  At baseline, the individuals who developed cognitive impairment 
has significantly lower levels of circulating beta-tocotrienol (adjusted for cholesterol 
levels) (mean standard ± deviation=8.3 ± 2.0 vs. 9.1 ± 2.3, p=0.028), as well as lower 
levels of γ-tocotrienol (46.8 ± 7.8 vs. 51.8 ± 9.6, p=0.001). However, after adjusting 
for age, gender, education level, APOE status, Body Mass Index, smoking, alcohol 
intake, and cardiovascular disease history, being in the highest tertile of circulating 
tocotrienols was not associated with 8-year cognitive impairment risk (all p-
values>0.05). With only the γ-tocopherol levels being inversely associated with 
cognitive impairment risk (adjusted HR=0.27, 95% CI: 0.10-0.78). The authors 
concluded that there could be a potential association between vitamin E and cognitive 
function in elderly individuals, however, the study sample was small and no power 
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calculation (either a priori or post hoc) was undertaken performed. Although  
adjustments for alcohol and smoking were undertaken to attempt to control for 
confounders, no dietary habits were taken into account so this could be seen to be a 
significant risk of bias(20).  
DNA damage 
Clinical trials 
A small number of in vitro studies have been conducted to investigate several roles of 
vitamin E on cell metabolism (i.e., angiogenesis, apoptosis, immuno-suppression, etc) 
with these providing positive data (21). However, only one randomized, double-
blinded clinical trial has been performed in elderly humans, which was undertaken in 
Malaysia. Sixty-four individuals were randomly assigned to receive either a 74% 
tocotrienol vitamin E supplement (160 mg/day), or a placebo capsule for six months. 
The study excluded smokers, those with significant disease, those taking medication, 
alcohol and/or other supplements. Information on the socio-economic characteristics 
was obtained together with their physical activity levels and dietary habits. DNA 
damage was measured through the total DNA damage score as proposed by 
Kobayashi et al. (22). Total DNA damage decreased significantly among the 
intervention group (p<0.001), but not in the placebo group (p>0.05). Additionally, the  
decrease in DNA damage appeared to be greater in the sub-group of older individuals 
(>50 years of age), p<0.001. The authors suggested that the protective effect of 
tocotrienols supplementation could be mainly attributed to its antioxidant properties 
and signaling properties, which lead to either lower DNA damage rate, or higher 
DNA repair rate. Despite the apparent efforts that the study researchers took to assess 
a range of several lifestyle confounders, no information was given on whether the two 
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groups differed in terms of lifestyle characteristics, such as physical activity, overall 
diet quality or vitamin E intake from food, were not taken into account (23). 
Osteoporosis 
The majority of the published research studying the effect of  tocotrienol on bone 
metabolism has been undertaken  in animal models (21, 24, 25), thus, it is out of the 
scope of the present review. To date are only three studies that investigated the impact 
of tocotrienol on human bone cell metabolism were found, with all of them being 
reports of in vitro studies. Brooks et al. in 2011 investigated the potential of vitamin E 
to prevent bone loss. Specifically, they compared different vitamin E homologues 
(tocotrienols isomers) to clinically used medication (biophosphonate and 
pamidronate) on human osteoclasts cultures. This demonstrated that osteoclastic 
resorption and γ-tocotrienol was found to inhibit osteoclast activity but not osteoclasts 
formation. Contrarily, α-tocotrienol was found to affect both activity and formation 
and thus could be defined toxic. The authors suggested that there is a potential anti-
resorptive action of γ-tocotrienol that warrants further investigation (26). A further 
study assessed the role of tocotrienols on human osteoclasts cultures was published in 
the same year and suggested biochemical pathways through which these vitamin E 
homologues act. Specifically, α-tocotrienol when added in osteoclasts cultures 
inhibited the ability of Receptor of NF-kB ligand (RANKL) to induce osteoclast 
differentiation. This suggested that α-tocotrienol can inhibit RANKL expression in 
osteoblasts probably through Prostagladin-E2 downstream molecules. Finally, α-
tocotrienol inhibits bone-resorbing activity of mature osteoclasts, which is attributed 
to its antioxidants capacity, which is unlikely to be reproducible in in vivo human 
studies. All those actions were only described for tocotrienols, but not for tocopherols, 
suggesting that tocotrienols could be in a pivotal point for bone metabolism (27). 
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Following the aforementioned suggestions for the antioxidant capacity of tocotrienols 
on bone metabolism, Nizar et al. evaluated the protection induced by tocotrienols 
against oxidative stress in bones' osteoblasts. The measuring outcome was cell 
viability after exposure to Hydrogen Hyperoxide. The study findings supported an 
important dose-related action, which could be toxic against osteoblasts in high γ-
tocotrienols concentrations, whilst in moderate concentrations was proved to protect 
against oxidative stress and thus, protect against unfavorable bone metabolism (28).  
4. DISCUSSION AND CONCLUSIONS 
4.1 Main findings 
There is growing evidence in the published literature to support the potential role 
of tocotrienols in healthy ageing. Specifically, case-control and prospective studies 
that evaluated the association between blood tocotrienols levels and cognitive 
function (Alzheimer’s disease and cognitive impairment) have revealed that increased 
circulating tocotrienols’ levels are associated with a protective effect against cognitive 
impairment and reduced risk of developing Alzheimer’s disease. Beneficial effects on 
biomarkers, has been studied in a clinical trial which investigated the effect of 6-
months tocotrienols’ supplementation on DNA damage rate. This study found a 
significant decrease in DNA damage in the intervention group, but not for the control 
group. A potential explanation of these associations could be the strong antioxidant 
activity of tocotrienols, since oxidative stress (i.e., imbalance of reactive species 
generation and innate antioxidant defense) can lead to neurodegenerative disorders 
and DNA damage (10). However, a mediator that could possibly explain the reduced 
risk of cognitive impairment offered by tocotrienols, is the Nuclear Factor kappa-B. 
This factor regulates genes linked to inflammation, cell cycle and apoptosis and its 
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dysregulation is implicated in unfavorable inflammatory responses (11), including 
ageing.  
With respect to osteoporosis, to date only bone cells cultures have been published 
for the role of tocotrienols in human osteoporosis, which showed a potential 
protective effect. To date, a clinical trial has been registered in 2014, is closed to 
reporting but has not yet been published (29). The in vitro studies the potential 
beneficial effects was proposed to be via the inhibition of osteoclasts with a 
simultaneous promotion of osteoblasts action (21). Potential in concordance with the 
data on reduced DNA damage, tocotrienol may be working in these in vitro 
experiments by the modification of the receptor activator of Nuclear Factor kappa-B 
against the genesis of osteoclasts, which is one half of the tocotrienols’ 
antiosteoporotic action. The other half is the antioxidant capacity, which prevents 
oxidative damage and protects osteoblast from early apoptosis which is plausible in 
vitro studies(12). It has been suggested that tocotrienols, if co-administered with 
statins could have a synergistic effect against osteoporosis, without reaching 
intolerable dosage for both agents (14, 16, 25, 30).  
4.2 Study limitations 
The majority of the reviewed studies assessed tocotrienols’ intake through the 
circulating tocotrienols levels rather than using supplementation dosage or dietary 
intake of the vitamin. To date, there is still a near complete lack of data to define what 
level of tocotrienols’ intake could lead to the potentially protective circulating levels 
of this agent in order to translate this finding into a useful consumer or clinical 
recommendation.  A key limitation of the data is that important confounders such as 
depressive symptomatology, physical activity, genetic predisposition, diet quality, 
smoking and other socio-economic parameters have not been taken into account.  
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4.3 Further research 
Well designed, larger controlled studies, which are able to assess a wide variety of 
potential confounders, are needed to confirm the presented results.  Future studies 
should also include pharmacokinetic trials of individual tocotrienols and their 
combination in order to provide insights into safe dosages and systemic absorption 
rates of these compounds. To gain a broad and full understanding a combination of 
further in vitro and  epidemiological studies are needed to develop hypotheses and 
mechanisms, whilst clinical trials are needed to provide insights into the dosage 
needed to achieve the protective effects, as well as the best subtype tocotrienols.  
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Figure 1. PRISMA flowchart showing the inclusion and exclusion of studies in the 
systematic review. 
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Table 1. Characteristics of epidemiological observational studies (n=10) and clinical trial (n=1) that evaluated the effect of tocotrienols intake 
diet on ageing (HR: Hazard Ratio; OR: Odds Ratio; CI: Confidence Interval). 
Study Country, 
year 
N Age, Sex 
 
Exposure Outcome Results 
Prospective studies (n=2) 
Mangialasche F. 
et al. (19). 
 
Sweden, 
2010 
232 >80 years of age 
 males and females 
 
Blood 
tocotrienols 
6-year Alzheimer’s 
Disease risk 
HR for alpha-
tocotrienol=0.70, 
95%CI: 0.44-1.11 
Mangialasche F. 
et al.(20) 
Finland, 
2013 
140 >80 years of age 
 males and females 
 
Blood 
tocotrienols 
8-year cognitive 
impairment risk 
HR for gamma-
tocotrienol=0.27, 
95%CI: 0.10-0.78 
Cross-sectional studies (n=1) 
Mangialasche F. 
et al. (18). 
 
Sweden, 
2012 
187 controls 166 
Mild Cognitive 
impairment 
>80 years of age 
 males and females 
 
Blood 
tocotrienols 
Mild cognitive 
impairment 
OR 3rd to 1st 
tertile=0.06, 95% CI: 
0.02-0.21. 
Clinical trial Country, 
year 
Intervention Age, Sex 
 
Duration  Results 
Chin et al. (23).  
 
Malaysia, 
2008 
74% tocotrienol 
supplement (160 
mg/day) vs. 
placebo capsule 
32/32 
Males and females 
6 months  For subjects >50 
years of age: Total 
DNA damage 
decreased 
significantly among 
the intervention 
group (p<0.001), but 
not in the placebo 
group (p>0.05).  
